Drug intelligence / Profile preview

SOCC-2

Development stage: Unknown
Lead developer: Xiamen Encheng Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

SOCC-2 is an investigational small molecule potassium-competitive acid blocker (P-CAB) developed by Xiamen Encheng Pharmaceutical for the treatment of acid-related gastrointestinal disorders. It functions by reversibly inhibiting the gastric H+/K+-ATPase (the proton pump) through competition with potassium ions. Unlike traditional proton pump inhibitors (PPIs), SOCC-2 does not require acid activation and provides a more rapid onset of action with sustained acid suppression. The drug is being evaluated for indications including gastroesophageal reflux disease (GERD), duodenal ulcers, gastric ulcers (including those associated with NSAIDs), and Helicobacter pylori infection.

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on SOCC-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOCC-2.

Explore the full profile